Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
- Cancer statistics, 2015.CA Cancer J Clin. 2015; 65: 5-29
- Adjuvant therapy for colorectal cancer: Present and future perspectives.Dis Colon Rectum. 1997; 40: 977-992
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data.Lancet Oncol. 2010; 11: 835-844
- Pharmacogenetics and pharmacogenomics: A bridge to individualized cancer therapy.Pharmacogenomics. 2013; 14: 315-324
- Single nucleotide polymorphism and its dynamics for pharmacogenomics.Interdiscip Sci. 2014; 6: 85-92
- Chemoradiation with novel agents for rectal cancer.Clin Colorectal Cancer. 2002; 2: 24-30
- Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systemic review.Colorectal Disease. 2016; 18: 234-246
- Molecular basis for 5-Fluorouracil-related toxicity: Lessons from clinical practice.Anticancer Research. 2014; 34: 1531-1535
- Novel approaches for targeting thymydiylate synthase to overcome the resistance and toxicity of anticancer drugs.J Med Chem. 2010; 53: 6539-6549
- Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 Study.J Clin Oncol. 2014; 32: 1031-1039
- Thymidlyate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.Pharmacogenomics J. 2001; 1: 65-70
- Identification and functional analysis of single nucleotide polymorphism in the tandem repeat seqeunce of thymidylate synthase gene.Cancer Res. 2003; 63: 6004-6007
- The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM.Ann Surg Oncol. 2010; 17: 1471-1474
- Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.Histopathology. 2005; 47: 141-146
- Predictive markers of response to neoadjuvant therapy in rectal cancer.J Surg Res. 2014; 194: 120-126
- Preoperative versus postoperative chemoradiotherapy for rectal cancer.New Engl J Med. 2004; 351: 1731-1740
- Dihydropirymidine dehydrogenase (DPD)—A toxicity marker for 5-fluorouracil?.Ann Acad Med Stetin. 2013; 59: 48-53
- The role of IVS14+1 G>A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer.Eur Rev Med Pharmacol Sci. 2012; 18: 1247-1258
- Dihydropyrmidine dehydrogenase deficiency and fluorouracil-related toxicity.Br J Cancer. 1997; 79: 627-630
- Clinical relevance of different dihydropyrmidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.Molecular Cancer Therapeutics. 2006; : 2895-2904
- Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers.Anticancer Research. 1999; 19: 3249-3252
- Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase.Cell Struct Funct. 1995; 20: 191-197
- Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.Int J Cancer. 2015; 138: 245-253
- Tailored selection of the interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: Analysis based on the pathological stage or chemoradiation response.J Cancer Res Clin Oncol. 2015; 141: 719-728
Supported by the National Cancer Institute grant R25-CA134283 (Nelson [PI, Hein]) and the John Williamson and Barbara Thurston Atwood Price Family Trust.
The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The authors declare no conflicts of interest.